Targeted Optical Imaging of the Glucagonlike Peptide 1 Receptor Using Exendin-4-IRDye 800CW.
congenital hyperinsulinism
exendin
fluorescence
insulinoma
optical imaging
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
29
07
2019
accepted:
13
11
2019
pubmed:
12
1
2020
medline:
29
12
2020
entrez:
12
1
2020
Statut:
ppublish
Résumé
The treatment of choice for insulinomas and focal lesions in congenital hyperinsulinism (CHI) is surgery. However, intraoperative detection can be challenging. This challenge could be overcome with intraoperative fluorescence imaging, which provides real-time lesion detection with a high spatial resolution. Here, a novel method for targeted near-infrared (NIR) fluorescence imaging of glucagonlike peptide 1 receptor (GLP-1R)-positive lesions, using the GLP-1 agonist exendin-4 labeled with IRDye 800CW, was examined in vitro and in vivo.
Identifiants
pubmed: 31924726
pii: jnumed.119.234542
doi: 10.2967/jnumed.119.234542
pmc: PMC7383075
doi:
Substances chimiques
Benzenesulfonates
0
Glucagon-Like Peptide-1 Receptor
0
IRDye 800CW
0
Indoles
0
Exenatide
9P1872D4OL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1066-1071Informations de copyright
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.
Références
J Magn Reson Imaging. 2017 Dec;46(6):1648-1655
pubmed: 28419614
Lancet Diabetes Endocrinol. 2013 Oct;1(2):115-22
pubmed: 24622317
Bioconjug Chem. 2014 Jul 16;25(7):1323-30
pubmed: 24856928
J Nucl Med. 2016 May;57(5):715-20
pubmed: 26795291
FEBS Lett. 1994 Jul 4;348(1):7-13
pubmed: 7517895
Pancreas. 2014 Jul;43(5):675-86
pubmed: 24921202
Med Klin (Munich). 1996 Jun 15;91(6):349-54
pubmed: 8767307
Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1345-55
pubmed: 20111963
Surgery. 2002 Dec;132(6):1040-9; discussion 1049
pubmed: 12490853
Ann Surg Oncol. 2010 Apr;17(4):1094-100
pubmed: 20033320
Br J Surg. 2015 Jan;102(2):e56-72
pubmed: 25627136
Acta Diabetol. 2017 Nov;54(11):1039-1045
pubmed: 28891030
Lancet Gastroenterol Hepatol. 2016 Dec;1(4):283-290
pubmed: 28404198
Lasers Med Sci. 2017 Nov;32(8):1909-1918
pubmed: 28900751
Expert Rev Anticancer Ther. 2016;16(1):71-81
pubmed: 26567611
Bioconjug Chem. 2010 Jul 21;21(7):1362-8
pubmed: 20583828
Contrast Media Mol Imaging. 2012 Mar-Apr;7(2):160-6
pubmed: 22434628
Contrast Media Mol Imaging. 2018 Aug 27;2018:2015237
pubmed: 30224903
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1593-600
pubmed: 26923247
Dtsch Med Wochenschr. 2004 Apr 23;129(17):941-6
pubmed: 15083396
Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12815-20
pubmed: 21768367
J Pediatr Surg. 2013 Feb;48(2):388-93
pubmed: 23414871
J Clin Endocrinol Metab. 2009 Nov;94(11):4398-405
pubmed: 19820010
J Neurooncol. 2018 Aug;139(1):135-143
pubmed: 29623552
Neoplasma. 2015;62(5):692-704
pubmed: 26278152
Clin Cancer Res. 2017 Jun 1;23(11):2730-2741
pubmed: 28119364
Diabetologia. 2014 May;57(5):950-9
pubmed: 24488022
Eur J Nucl Med Mol Imaging. 2003 May;30(5):781-93
pubmed: 12707737
J Inherit Metab Dis. 2012 Jul;35(4):589-601
pubmed: 22231386
EJNMMI Res. 2014 Jun 22;4:31
pubmed: 25006548
J Clin Endocrinol Metab. 2013 Nov;98(11):E1786-9
pubmed: 24057290
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2318-2327
pubmed: 30054698